U.K.-based CRO Albany Molecular Research, a wholly owned subsidiary of AMRI, has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory, acting on behalf of the U.K.'s Secretary of State for Defense, the Department of National Defense of Canada and Minister of Defense of the Kingdom of the Netherlands.

AMRI initially will work on the development and scale-up of the investigational drug, and subsequently the manufacture and supply for use during phase I clinical trials. If the trials are successful, AMRI will be in position to become the commercial manufacturer of the product for distribution to the government partners of this contract including the U.K., Netherlands and Canada.